BeSafe研究:BeFlared桥接支架用于开窗EVAR的早期结果
BeSafe多中心前瞻性研究纳入11个中心84例开窗腔内动脉瘤修复(FEVAR)患者,均使用新型BeFlared桥接支架。靶血管置管失败率0.6%,术后1个月免于靶血管不稳定率达99.3%,早期安全性和有效性良好。
要点
- BeFlared桥接支架在FEVAR中技术成功率高,靶血管置管失败率仅0.6%。
- 术后1个月免于靶血管不稳定(TVI)率为99.3%,无支架闭塞或断裂。
- 术中13例支架需二次扩张,6例靶血管额外植入支架。
核心结论
- BeFlared桥接支架在FEVAR中显示出良好的早期安全性和有效性。
研究设计与样本
- 多中心前瞻性研究,纳入2024年11月至2025年4月间11个高容量中心连续接受FEVAR并使用BeFlared作为桥接支架的患者84例(75例男性,年龄73.2±7.3岁)。
主要发现
- 312个靶血管中2个(0.6%)置管失败,置管成功的310个靶血管均成功植入BeFlared支架。
- 术中13个(4.2%)BeFlared支架需二次扩张,6个(1.9%)靶血管额外植入支架。
- 平均手术时间162±60分钟。
- 术后CT血管造影确认术中1例(0.3%)肾动脉Ic型内漏待再干预,并发现1例(0.3%)肾动脉支架狭窄,无支架闭塞、扭结、断裂或支架相关二次手术。
- 术后1个月免于靶血管不稳定(TVI)率为99.3%。
临床怎么用
- 对于需要桥接支架的FEVAR患者,BeFlared可作为早期安全有效的选择,但需注意术中可能需要二次扩张或额外植入支架。
局限性
- 随访时间仅1个月,为早期结果,长期耐久性尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to report the early outcomes of fenestrated endovascular aneurysm repair (FEVAR) performed with the BeFlared bridging stent (Bentley, Hechingen, Germany), a new dedicated bridging stent mounted on a stepped balloon. METHODS: The study included consecutive patients treated by FEVAR exclusively performed with BeFlared as the bridging stent at 11 high volume centres between November 2024 and April 2025. Patient demographics, target vessel (TV) anatomy, and post-operative patient and stent outcomes were collected prospectively in an electronic database. Computed tomography angiography (CTA) imaging was performed within the first post-operative month. The composite primary endpoint was the freedom from target vessel instability (TVI) rate. RESULTS: Eighty-four patients were included (75 men, 73.2 ± 7.3 years). TV catheterisation failed in two of 312 (0.6%) TVs. BeFlared stenting was successful in all cases after TV catheterisation (n = 310). During the procedure, 13 BeFlared stents (4.2%) required secondary inflation and additional stents were implanted in six TVs (1.9%). The mean procedural time was 162 ± 60 minutes. On completion angiography, all stents were patent and one renal type Ic endoleak was noted (0.3%). Post-operative CTA confirmed the intra-operative type Ic endoleak (0.3%), which is pending re-intervention, and additionally revealed one renal stent stenosis (0.3%). There were no stent occlusions, kinking, fracture, or stent related secondary procedures, resulting in a 99.3% freedom from TVI at one month. CONCLUSION: In this first multicentre, prospective clinical report involving 84 patients treated across 11 expert centres, the BeFlared bridging stent demonstrated favourable early safety and effectiveness.
引用
- Oliny A, Marques de Marino P, Resch TA, et al. Early Results from the BeSafe Multicentre Prospective Study Evaluating a New Dedicated Bridging Stent for Fenestrated Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg. 2025. PMID: 41197943. doi:10.1016/j.ejvs.2025.10.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。